To evaluate the cross protection conferred by pooled anti-lipopolysaccharide antibodies in human sera against a challenge with a specific lipopolysaccharide (LPS) endotoxin. Methods Three groups, each comprising of fifteen weight and sex matched Tuck-ordinary (T.O) mice were passively immunized intraperitoneally with 0.25 ml of 0.15M sterile PBS saline, 0.25 ml of high titer J5 (mutant E.coli 0111:B4) LPS antiserum, and 0.25 ml of high titer concoction LPS antiserum containing a mixture of antibodies against four different endotoxins. After one hour all mice received intraperitoneal injection of 5 g (LD-100) LPS from Salmonella abortus equii in sterile PBS containing 10 mg D-galactosamine. Survival of mice was assessed at four hourly intervals for 24 hours. Mice surviving 24 hours after administration of LPS were considered as protected. Conclusion Concoction LPS antiserum was able to provide 100% protection since all the mice in that group survived at the end of 24 hours. E.coli J5-LPS antiserum could protect only nine out of fifteen mice (60%), whereas none of the mice survived in the group that received normal saline (p 0.0001, 2 =30.53).
Introduction
nfections caused by gram negative bacteria constitute one of the major causes of the sepsis syndrome, characterized by hypotension, tachycardia, tachypnea, disseminated intra vascular coagulation, and multiple organ system failureP 1 P . Gramnegative bacterial sepsis is a serious complication especially in patients with burns, trauma and post-operative cases of abdominal surgery in intensive care units. Although antibiotic therapy plays an important role in limiting the incidence of this complication, there has been a little change in the mortality of this condition once developedP 2 P . The mortality rate for septic shock patients continues to be unacceptably high, in spite of the therapeutic intervention and rigorous supportive careP 3, 4 P . It is generally acknowledged that the systemic inflammatory response associated with gram-negative bacterial infection is triggered by the release of lipopolysaccharide (LPS) from bacterial cell wallP 5 P . LPS is the main component of the outer membrane of the cell wall of gramnegative bacteria and is believed to be responsible for the initiation of endotoxic shock. The systemic administration of LPS has been commonly used in experimental animals to reproduce the typical feature of clinical septic shock, including the production of pro-inflammatory mediatorsP 6,7 P .P P Therefore this molecule has been targeted for development of new preventive and therapeutic strategy P 8 P . It has been found that endotoxins derived from different bacterial species share a common basic structure P 9 P . LPS consists of a polysaccharide part that includes an Ospecific chain and core oligosacchride (OS) linked in a covalent bond to lipid AP 10 P . Most of the antibodies produced during immunization with bacterial cells are directed against the O-specific part of endotoxin. 
Materials and Methods
U Screening for High Titer Human Antisera Antisera were obtained from the routine blood samples sent to the laboratory for other investigations. All the sera were screened for E.coli J5 LPS and the concoction LPS antibodies using enzyme-linked immunosorbent assay (ELISA) technique P 12 P . Briefly, ELISA plates (Immulon M129, Dynatech) were coated with 20 g/ml of either E.coli 0111:B4 J5 mutant Rc chemotype LPS at 1mg/ml in pyrogen free water or E.coli EH100, Salmonella minnesota Re595, Salmonella typhimurium SL684 and Shigella flexneri were diluted 1mg/ml in pyrogen free water and used as a combination of LPS (Sigma) overnight at room temperature. The plates were incubated for 1 hour with 1% pyrogen-free BSA at 37 to block nonspecific binding and washed three times with washing buffer (0.1% Tween20 containing 0.05 % Sodium azide and 0.02M Magnesium Chloride (MgCl). Following this, 100 l of test sera were dispensed in the in micro-titer plate and incubated (1 hour at 37 C). Plates were then washed five times in washing buffer then 100 l alkaline phosphatase conjugate anti human IgG was added to plates and incubated (1 hour at 37 C). At the end of incubation period the plates were washed five times with washing buffer. Finally, alkaline phosphatase substrate (Sigma) was added to all the wells and optical density was obtained using 405nm I filter. Sera containing IgG to E.coli J5 LPS and the cocktail LPS either equal to or more than a titer of 1:2560 were collected and used in the experiment.
Mouse Protection Studies
Three groups of fifteen Tuck Ordinary (T.O) mice each matched for weight, age and sex (Harlan Olac, UK) were used in the study. Each group of mice received an intraperitoneal injection of either 0.25 ml of 0.15M sterile PBS, 0.25 ml (dose calculated earlier by series of titration) of high titer anti J5 serum or 0.25 ml of high titer anti concoction serum. An hour later, all mice were injected intraperitonially with a lethal dose of 5 g of commercially obtained pure LPS (Sigma product, UK) from Salmonella abortus equii in sterile PBS containing 10 mg D-galactosamine lethal dose (LD100) in 24 hours. This dose was determined prior to experimenting on mice through series of dilutions. Mice were kept in separate cages and examined at four hourly intervals. Mice surviving 24 hours after administration of LPS were considered protected. Statistical significance was assessed by Chi square test. Figure 1 shows the result of protection conferred by anti LPS sera against septic shock inflicted by the lethal dose challenge with Salmonella abortus equii. Over 24-hour period, none of the mice survived the challenge in the group immunized by PBS saline. Pooled human anti E.coli J5 sera, however, provided 60% protection (out of 15 mice 9 survived). On the other hand, pooled human anti concoction serum provided 100% protection (p<0.0001, 2 =30.53), where all the 15 mice had survived 24 hours after the challenge with Salmonella abortus equii LPS ( Table 1 ). 
Results

Discussion
This study shows that anti concoction LPS serum effectively provides protection against gram negative septic syndrome, whereas the anti E.coli J5 serum provided a less efficient protection. The idea of targeting rough mutant antibodies as broadly cross protective therapy gained popularity with the report that equine antiserum raised against Salmonella strain of the Ra chemo type protected mice against challenge with virulent strain of Klebsiella pneumoniae 13 . However, due to the fact that immunodominant epitope in E.coli J5 (Rc) chemotype is the most conserved among gram negative organisms, it has been used in most investigations of cross protection by rough mutant organism 14 . Passive immunization with J5 was reported to provide partial protection to experimental animals against toxic effects of LPS [15] [16] [17] [18] .The same partial protection was reported against lethal gram negative bacteremia 19, 20 . Previous animal model studies conducted on a large scale showed that E.coli J5 antiserum could offer only 56-59% protection 15, 21 . Although a small number of mice were used in this study the protection offered by E.coli-J5 antibodies was similar (60%), suggesting that antiserum comprising of IgG against a single organism LPS provides partial cross protection against gram negative sepsis.
Since the sharing of bacterial antigens across the species is a well known phenomenon and in order to increase achieved cross protection using antisera, it would appear logical to use antiserum that contains immunoglobulins against LPS from more than one organism 11 . A pervious study using the antisera comprising of immunoglobulins against two organisms failed to show any enhancement in the protection of animals against gram negative sepsis 22 . These finding are in contradiction to what was observed in the present study, where a concoction of immunoglobulins against four different organisms proved to be more effective compared to the antisera containing IgGs against a single organism. The difference could be due to the fact that the anti serum used in the previous studies 18,22 was derived from animal source whereas the antiserum used in the present study was of human origin. The difference in the ability of human and animal immune response to react to foreign antigens may be responsible for the discrepancy of results observed in the studies. Despite some contradictions in previous experimental findings, there is evidence that anti core antibodies protect in clinical settings, as illustrated in recent studies which show that high levels of natural anti-LPS core antibodies correlate with reduced incidence of complications after surgery and better outcomes from infection 23 -25 .
In the study using concoction LPS was shown to confer complete cross-protection against lethal challenge with LPS. Despite of the fact that the concoction LPS did not contain anti LPS antibodies specific to the LPS used for the lethal challenge, the concoction LPS appeared to have the ability to protect the mice efficiently. Because of shared antigens among different gram negative LPS further studies are needed to elucidate the role of pooled human anti sera containing anti LPS antibodies against various organisms as a potential therapeutic agent. The fact that the anti human sera used in this study was collected from blood specimens would open a new venue in mass screening of blood donors for the presence of relevant protective antibodies that could provide effective protection in septic shock syndrome. Recent study has demonstrated that the cyanobacterial LPS analogue, CyP, has inhibited E.coli LPS-induced cytokines as an inflammatory agent 26 . Other studies have illustrated that a combined inhibition of complement and CD14 abolish E.coli-induced inflammatory response in human blood 7, 27 . On the other hand, some have argued that the cooperative interplay between the LPSbinding protein (LBP), the membrane-bound of CD14 and TLRs are required to trigger a pro-inflammatory response which is crucial for keeping infection under control 28 . Finally, a combination therapy of anti bacterial drugs, anti concoction LPS and anti-inflammatory agents might be suggested for optimal treatment to overcome the complexity of sepsis.
